{"title": "EpiVax avanza en una vacuna para abordar las variantes del SARS-CoV-2", "author": "Europa Press", "url": "https://www.notimerica.com/comunicados/noticia-comunicado-epivax-avanza-vacuna-abordar-variantes-sars-cov-20211201083258.html", "hostname": "notimerica.com", "description": "PROVIDENCE, R.I., 1 de diciembre de 2021 /PRNewswire/ -- Hoy, EpiVax, Inc. (\"EpiVax\") confirm\u00f3 que los...", "sitename": "notimerica.com", "date": "2021-12-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "PROVIDENCE, R.I., 1 de diciembre de 2021 /PRNewswire/ -- Hoy, EpiVax, Inc. (\"EpiVax\") confirm\u00f3 que los ep\u00edtopos de la vacuna\n[EPV-CoV-19](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=1599312354&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D2470375866%26u%3Dhttps%253A%252F%252Fepivax.com%252Fpipeline%252Fepv-cov19%26a%3DEPV-CoV-19&a=EPV-CoV-19) de la compa\u00f1\u00eda est\u00e1n conservados en un 98,2% en la nueva variante Omicron SARS-CoV-2. EpiVax y EpiVax Therapeutics, Inc. (\"EVT\") tambi\u00e9n est\u00e1n afirmando el compromiso de trasladar la nueva vacuna del ep\u00edtopo de c\u00e9lulas T a la cl\u00ednica en 2022. EPV-CoV-19 est\u00e1 dise\u00f1ado para usarse para proteger contra variantes de preocupaci\u00f3n (VOC) despu\u00e9s de la exposici\u00f3n al SARS-CoV-2 o la vacunaci\u00f3n y se est\u00e1 acercando a la fase cl\u00ednica de desarrollo mientras se finalizan la formulaci\u00f3n, la presentaci\u00f3n del IND y el protocolo del ensayo cl\u00ednico.\nEPV-CoV-19 aumentar\u00e1 la respuesta de las c\u00e9lulas T, un factor clave para la protecci\u00f3n inmunol\u00f3gica contra el SARS-CoV-2. Utilizando herramientas inmunoinform\u00e1ticas patentadas, EpiVax seleccion\u00f3 secuencias altamente inmunog\u00e9nicas (ep\u00edtopos de c\u00e9lulas T) conservadas en todos los nuevos tipos de SARS-COV-2, incluidos alfa, beta, gamma, delta y \u00f3micron. El an\u00e1lisis de hoy de 188.758 secuencias de SARS-CoV-2 revel\u00f3 que los ep\u00edtopos de la vacuna se conservan en un 97-99% contra VOC. A pesar del elevado n\u00famero de mutaciones en Omicron VOC, se espera que solo tres de 164 ep\u00edtopos de vacunas sean ineficaces para proteger contra Omicron VOC.\nLa mayor\u00eda de los desarrolladores de vacunas COVID se han centrado en la respuesta de anticuerpos al virus pand\u00e9mico, mientras que los expertos de EpiVax, l\u00edderes mundiales en dise\u00f1o de vacunas computacionales, han observado firmemente que las respuestas de c\u00e9lulas T inducidas por la vacuna desempe\u00f1an un papel importante en la protecci\u00f3n proporcionada por la exposici\u00f3n y la vacunaci\u00f3n. EpiVax se centr\u00f3 en identificar los ep\u00edtopos de la m\u00e1s alta calidad (altamente inmunog\u00e9nicos) que se conservan de forma cruzada entre las cepas de coronavirus, para crear una vacuna que probablemente sea eficaz contra todas las variantes del SARS-CoV-2 identificadas hasta la fecha o que surjan pronto, incluido Omicron y la vacuna. Se demostr\u00f3 que los\n[ep\u00edtopos son eficaces en estudios in vitro en humanos y murinos in vivo](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=1430374213&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D1616622336%26u%3Dhttps%253A%252F%252Fdoi.org%252F10.1038%252Fs41541-021-00331-6%26a%3Dthe%2Bvaccine%2Bepitopes%2Bwere%2Bshown%2Bto%2Bbe%2Beffective%2Bin%2Bhuman%2Bin%2Bvitro%2Band%2Bmurine%2Bin%2Bvivo%2Bstudies.&a=ep%C3%ADtopos+son+eficaces+en+estudios+in+vitro+en+humanos+y+murinos+in+vivo). EPV-CoV-19 ha sido licenciada a EVT, una empresa privada respaldada por inversores que tambi\u00e9n se encuentra en RI.\nAcerca de EpiVax:\nEpiVax es una empresa de biotecnolog\u00eda con experiencia en predicci\u00f3n de epitopos de c\u00e9lulas T, modulaci\u00f3n inmune y dise\u00f1o r\u00e1pido de vacunas. Los kits de herramientas de detecci\u00f3n de inmunogenicidad de EpiVax para terapias y vacunas,\n[ISPRI](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=1917039753&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D3941252748%26u%3Dhttps%253A%252F%252Fepivax.com%252Fimmunogenicity-assessment%252Fispri-web-based-immunogenicity-screening%26a%3DISPRI&a=ISPRI) e [iVAX](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=3043837496&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D890433383%26u%3Dhttps%253A%252F%252Fepivax.com%252Fimmunogenicity-assessment%252Fivax-web-based-vaccine-design%26a%3DiVAX&a=iVAX), se emplean para avanzar en la investigaci\u00f3n de una lista global de empresas.\nPara m\u00e1s informaci\u00f3n sobre EpiVax, visite\n[www.epivax.com](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=3613716169&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D3805456206%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3024498-1%2526h%253D4221479564%2526u%253Dhttp%25253A%25252F%25252Fwww.epivax.com%25252F%2526a%253Dwww.epivax.com%26a%3Dwww.epivax.com&a=www.epivax.com).\nAcerca de EVT:\nEVT emplea tecnolog\u00eda l\u00edder mundial de EpiVax para dise\u00f1ar terapias que activan las c\u00e9lulas T para curar o prevenir enfermedades. La cartera de EVT incluye una vacuna COVID-19 y una vacuna personalizada contra el c\u00e1ncer de vejiga. Para obtener m\u00e1s informaci\u00f3n sobre EPV-CoV-19, visite\n[este enlace](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=3476125148&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D66216306%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3024498-1%2526h%253D2766501294%2526u%253Dhttps%25253A%25252F%25252Fepivax.com%25252Fpipeline%25252Fepv-cov19%2526a%253Dthis%252Blink%26a%3Dthis%2Blink&a=este+enlace) o comun\u00edquese con [Nicole Ruggiero], directora de operaciones de EVT.\nPara m\u00e1s informaci\u00f3n sobre EVT, visite\n[www.epivaxtx.com](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=246985044&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D799765182%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3024498-1%2526h%253D4209988116%2526u%253Dhttps%25253A%25252F%25252Fwww.epivaxtx.com%25252F%2526a%253Dwww.epivaxtx.com%26a%3Dwww.epivaxtx.com&a=www.epivaxtx.com). [Haga clic aqu\u00ed para ver una versi\u00f3n ampliada de este comunicado.](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=4206662857&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D1927886753%26u%3Dhttps%253A%252F%252Fepivax.com%252Fnews%252Fepivax-continues-to-progress-on-a-vaccine-to-address-sars-cov-2-variants%26a%3DClick%2Bhere%2Bfor%2Ban%2Bexpanded%2Bversion%2Bof%2Bthis%2Brelease.&a=Haga+clic+aqu%C3%AD+para+ver+una+versi%C3%B3n+ampliada+de+este+comunicado.)\nContacto de prensa:Katie Porter, directora de Desarrollo Comercial EpiVax\n[kporter@epivax.com]\nLogo -\n[https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=429725515&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D4208724048%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F542055%252FEpiVax_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F542055%252FEpiVax_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F542055%2FEpiVax_Logo.jpg)", "language": null, "image": "https://img.europapress.es/fotoweb/fotonoticia_20211201083258_1200.jpg", "pagetype": "webpage", "links": ["https://twitter.com/notimerica", "https://www.facebook.com/Notimerica", "https://www.linkedin.com/company/europa-press", "https://www.notimerica.com", "https://www.notimerica.com/", "https://www.notimerica.com/comunicados/", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=1599312354&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D2470375866%26u%3Dhttps%253A%252F%252Fepivax.com%252Fpipeline%252Fepv-cov19%26a%3DEPV-CoV-19&a=EPV-CoV-19", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=1430374213&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D1616622336%26u%3Dhttps%253A%252F%252Fdoi.org%252F10.1038%252Fs41541-021-00331-6%26a%3Dthe%2Bvaccine%2Bepitopes%2Bwere%2Bshown%2Bto%2Bbe%2Beffective%2Bin%2Bhuman%2Bin%2Bvitro%2Band%2Bmurine%2Bin%2Bvivo%2Bstudies.&a=ep%C3%ADtopos+son+eficaces+en+estudios+in+vitro+en+humanos+y+murinos+in+vivo", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=1917039753&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D3941252748%26u%3Dhttps%253A%252F%252Fepivax.com%252Fimmunogenicity-assessment%252Fispri-web-based-immunogenicity-screening%26a%3DISPRI&a=ISPRI", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=3043837496&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D890433383%26u%3Dhttps%253A%252F%252Fepivax.com%252Fimmunogenicity-assessment%252Fivax-web-based-vaccine-design%26a%3DiVAX&a=iVAX", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=3613716169&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D3805456206%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3024498-1%2526h%253D4221479564%2526u%253Dhttp%25253A%25252F%25252Fwww.epivax.com%25252F%2526a%253Dwww.epivax.com%26a%3Dwww.epivax.com&a=www.epivax.com", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=3476125148&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D66216306%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3024498-1%2526h%253D2766501294%2526u%253Dhttps%25253A%25252F%25252Fepivax.com%25252Fpipeline%25252Fepv-cov19%2526a%253Dthis%252Blink%26a%3Dthis%2Blink&a=este+enlace", null, "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=246985044&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D799765182%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3024498-1%2526h%253D4209988116%2526u%253Dhttps%25253A%25252F%25252Fwww.epivaxtx.com%25252F%2526a%253Dwww.epivaxtx.com%26a%3Dwww.epivaxtx.com&a=www.epivaxtx.com", "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=4206662857&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D1927886753%26u%3Dhttps%253A%252F%252Fepivax.com%252Fnews%252Fepivax-continues-to-progress-on-a-vaccine-to-address-sars-cov-2-variants%26a%3DClick%2Bhere%2Bfor%2Ban%2Bexpanded%2Bversion%2Bof%2Bthis%2Brelease.&a=Haga+clic+aqu%C3%AD+para+ver+una+versi%C3%B3n+ampliada+de+este+comunicado.", null, "https://c212.net/c/link/?t=0&l=es&o=3374427-1&h=429725515&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3374427-1%26h%3D4208724048%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F542055%252FEpiVax_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F542055%252FEpiVax_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F542055%2FEpiVax_Logo.jpg", "https://www.segib.org/\r\n", "#", "#", "#", "#", "https://www.notimerica.com", "https://www.noticiargentina.com.ar/", "https://www.notibolivia.bo/", "https://www.notichile.cl/", "https://www.colombiapress.co", "https://www.notiecuador.com.ec", "https://www.notimexico.com.mx/", "https://www.notipanama.com.pa/", "https://www.notiparaguay.com.py", "https://www.notiperu.com.pe", "https://www.notiuruguay.uy", "https://www.notimerica.com/acercade.html", "https://www.notimerica.com/avisolegal.html", "https://www.notimerica.com/politica-cookies.html", "https://www.notimerica.com/politica-privacidad.html", "https://play.google.com/store/newsstand/news/Europa_Press?id=CAowubafCQ"]}